1
|
Wenger M, Sharp R, McCollum A, De Stefano L, Rhoten S, Worth T. Negative impacts of iron deficiency on visual category learning quantified in terms of dopaminergic status and brain energy expenditure. J Vis 2019. [DOI: 10.1167/19.10.244c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- Michael Wenger
- Psychology, The University of Oklahoma
- Cellular & Behavioral Neurobiology, The University of Oklahoma
| | | | | | - Lisa De Stefano
- Psychology, The University of Oklahoma
- Cellular & Behavioral Neurobiology, The University of Oklahoma
| | | | - Tory Worth
- Center for Cognitive Neuroscience, Duke University
| |
Collapse
|
2
|
McCollum A, Nakazawa Y, Ndongala GM, Pukuta E, Karhemere S, Lushima RS, Ilunga BK, Kabamba J, Li Y, Damon I, Carroll D, Reynolds M, Malekani J, Tamfum JJM. Human monkeypox in the Kivus, a conflict region of The Democratic Republic of the Congo. Int J Infect Dis 2014. [DOI: 10.1016/j.ijid.2014.03.820] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
3
|
Reynolds M, Malekani J, Damon I, Monroe B, Kabamba J, Lushima RS, Nguete B, Karhemere S, Pukuta E, Tack D, McCollum A, Bass J, Wemakoy O. Training health workers for enhanced monkeypox surveillance, Democratic Republic of the Congo. Int J Infect Dis 2014. [DOI: 10.1016/j.ijid.2014.03.990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
5
|
Agarwala AK, Hanna N, McCollum A, Bechar N, DiMaio M, Yu M, Tong Y, Becerra CR, Choy H. Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4557] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4557 Background: Pre-operative chemoradiotherapy (CRT) followed by surgical resection is a standard treatment option for pts with resectable esophageal or GE junction (GEJ) carcinomas (CA). Cetuximab, when combined with XRT is effective treatment for locally advanced cancers of the head and neck. We conducted this study to evaluate this regimen in pts with esophageal and GEJ CA. Methods: This is a single arm, open label pilot study combining cetuximab with XRT for pts with resectable esophageal and GEJ CA. The primary objective is to determine the pathologic complete response rate (pCR) (null hypothesis: p=0.20; alternative hypothesis: p=0.35) and determine the feasibility and toxicity of this regimen when given prior to esophagectomy. Key eligibility criteria are: squamous cell (SC)or adenoCA of the esophagus or GEJ, ECOG PS 0–2, clinical stage II -IVa, and eligible for esophagectomy. Pts received a loading dose of cetuximab at 400mg/m2 2 weeks prior to XRT, then weekly at 250 mg/m2 starting one week prior to XRT until completion of 50.4 Gy XRT. After satisfactory recovery, pts had esophagectomy. Results: Patient characteristics (n=40): median age 65 years (range, 54–82); 92% male; PS 0/1 63%/32%; esophageal/GEJ 65%/35%; adenoCA/SC 78%/22%; 36 pts have completed cetuximab and radiation and 26 pts have undergone esophagectomy. Of the 26 pts that have undergone esophagectomy, 13 obtained a pCR. 5/13 SC had pCR and 8/13 adenoCA had pCR. 10 pts did not undergo surgery for various reasons including disease progression (n=7), AE unrelated to treatment (n=2), and personal decision to forgo esophagectomy (n=1). 4 patients are still completing cetuximab/XRT. The most common G3 adverse event was rash (56%). Other G3 toxicities were infrequent and included dysphagia (6%), infection (6%), and GI bleed (3%). There have been no treatment or surgery related deaths. Conclusions: Cetuximab and XRT results in pCR's in pts with esophageal and GEJ CA (rate of pCR 13/36), including patients with either SC or adenoCA histologies. G3/4 toxicities, including dysphagia were generally uncommon. Further study of this combination prior to esophagectomy is warranted. [Table: see text]
Collapse
Affiliation(s)
- A. K. Agarwala
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - N. Hanna
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - A. McCollum
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - N. Bechar
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - M. DiMaio
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - M. Yu
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - Y. Tong
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - C. R. Becerra
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| | - H. Choy
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor Sammons Cancer Center, Dallas, TX; Community Oncology Center, Kokomo, IN; UT Southwestern Medical Center at Dallas, Dallas, TX; Indiana University School of Medicine, Indianapolis, IN
| |
Collapse
|
7
|
Erlichman C, Toft D, Reid J, Goetz M, Ames M, Mandrekar S, Ajei A, McCollum A, Ivy P. A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3030] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Erlichman
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - D. Toft
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - J. Reid
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - M. Goetz
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - M. Ames
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - S. Mandrekar
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - A. Ajei
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - A. McCollum
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| | - P. Ivy
- Mayo Clinic in Rochester, Rochester, MN; National Cancer Institute/NIH, Rockville, MD
| |
Collapse
|
8
|
Mitchell T, Plonczynski M, McCollum A, Hardy CL, Safaya S, Steinberg MH. Gene Expression Profiling during Erythroid Differentiation of K562 Cells. Blood Cells Mol Dis 2001; 27:309-19. [PMID: 11358393 DOI: 10.1006/bcmd.2000.0377] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We studied the temporal changes in gene expression in K562 cells at intervals from 2 to 48 h following induction using differential display polymerase chain reaction and gene expression arrays. More than 110 cDNA fragments representing 86 unique mRNAs were either up- or downregulated during erythroid differentiation. Sixty-one of the differentially expressed cDNA fragments had more than 95% homology to known GenBank sequences; 21 represented cDNA sequences with only dbEST or high-throughput gene-screening database matches. Four fragments had no database matches. Using gene expression arrays, 73 differentially expressed genes were observed. Unique expressed sequence tags (ESTs) were used to "clone" two novel genes from available databases and their tissue expression was examined. Erythroid maturation in induced K562 cells is associated with differential expression of many genes. Some differentially expressed clones were transcription factors and 25 expressed fragments with open reading frames were found whose function remains unknown.
Collapse
Affiliation(s)
- T Mitchell
- G.V. (Sonny) Montgomery Department of Veterans Affairs Medical Center, University of Mississippi School of Medicine, Jackson, Mississippi 39216, USA
| | | | | | | | | | | |
Collapse
|